Document:

Sixth Agreement to Amend the Recapitalization Support Agreement

 Exhibit 10.1 
 Execution Version 
 SIXTH AGREEMENT TO AMEND THE RECAPITALIZATION
SUPPORT AGREEMENT 
 THIS SIXTH AMENDMENT is made as of this 22nd day of April, 2011. 

WHEREAS, (a) Angiotech Pharmaceuticals, Inc. (“Angiotech”), (b) the entities listed in Schedule
A (together with Angiotech, the “Companies” and each a “Company”), and (c) each of the other Consenting Noteholders party hereto, each Consenting Noteholder being a holder of and/or investment advisor or
manager with investment discretion over Subordinated Notes, executed a Recapitalization Support Agreement dated as of October 29, 2010 concerning the principal aspects of a Recapitalization of the Companies (as amended by the First Amendment,
the Second Amendment, the Third Amendment, the Fourth Amendment and the Fifth Amendment, the “Support Agreement”); 
 AND WHEREAS, pursuant to Section 16(n) of the Support Agreement, the Support Agreement may be modified, amended or supplemented as to any matter by an instrument in writing signed by the
Companies and Consenting Noteholders that represent not less than a majority of the aggregate principal amount of Subordinated Notes; 
 AND WHEREAS, Consenting Noteholders representing not less than a majority of the aggregate principal amount of Subordinated Notes executed an Agreement to Amend the Recapitalization Support
Agreement dated as of November 29, 2010 (the “First Amendment”); 
 AND WHEREAS, Consenting
Noteholders representing not less than a majority of the aggregate principal amount of Subordinated Notes executed a Second Agreement to Amend the Recapitalization Support Agreement dated as of December 15, 2010 (the “Second
Amendment”); 
 AND WHEREAS, Consenting Noteholders representing not less than a majority of the aggregate
principal amount of Subordinated Notes executed a Third Agreement to Amend the Recapitalization Support Agreement dated as of January 11, 2011 (the “Third Amendment”); 

AND WHEREAS, Consenting Noteholders representing not less than a majority of the aggregate principal amount of Subordinated Notes
executed a Fourth Agreement to Amend the Recapitalization Support Agreement dated as of January 27, 2011 (the “Fourth Amendment”); 
 AND WHEREAS, Consenting Noteholders representing not less than a majority of the aggregate principal amount of Subordinated Notes executed a Fifth Agreement to Amend the Recapitalization Support
Agreement dated as of February 7, 2011 (the “Fifth Amendment”); 
 AND WHEREAS, the Companies and
the Consenting Noteholders party to this sixth amendment (the “Sixth Amendment”) wish to further amend the Support Agreement in the manner set out in this Sixth Amendment; 

 AND WHEREAS, the Consenting Noteholders party to the Sixth Amendment collectively
hold and/or exercise investment discretion over not less than a majority of the aggregate principal amount of outstanding Subordinated Notes; 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Companies and the Consenting Noteholders party hereto hereby agree as follows:

  

	1.	Capitalized Terms 

Capitalized terms that are used but not otherwise defined herein shall have the meanings ascribed thereto in the Support Agreement.

  

	2.	Consenting Noteholders Party to this Sixth Amendment 

 Each Consenting Noteholder party to this Sixth Amendment hereby represents and warrants, severally and not jointly, to each of the other parties to this Sixth Amendment (and acknowledges that each of the
other parties to this Sixth Amendment is relying upon such representations and warranties) that as of the date hereof: (a) it either (i) is the sole legal and beneficial owner of the principal amount of Subordinated Notes disclosed to
Goodmans as of such date, or (ii) has the investment and voting discretion with respect to the principal amount of Subordinated Notes disclosed to Goodmans as of such date; (b) it has the power and authority to bind the beneficial owner(s)
of such Subordinated Notes to the terms of this Sixth Amendment; and (c) it has authorized and instructed Goodmans to advise Angiotech, in writing, of the aggregate amount of Subordinated Notes held by the Consenting Noteholders that are party
to this Sixth Amendment. 
  

	3.	Amendments to the Support Agreement 

 The Support Agreement is hereby amended as follows: 
  

	 	(a)	the definition of “Outside Date” on Schedule B to the Support Agreement is hereby deleted and replaced with the following: 

“Outside Date” means May 12, 2011. 
  

	4.	Support Agreement to apply in full force and effect 

 Except as expressly modified by the terms of this Sixth Amendment, the terms and conditions of the Support Agreement shall continue to apply in full force and effect, unamended. 

 

	5.	Miscellaneous 

  

	 	(a)	This Sixth Amendment may be modified, amended or supplemented as to any matter by an instrument in writing signed by the Companies and Consenting Noteholders that
represent not less than a majority of the aggregate principal amount of Subordinated Notes. 

  
 - 2 -

	 	(b)	This Sixth Amendment shall be governed by and construed in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein,
without regard to principles of conflicts of law. Each of the parties to this Sixth Amendment submits to the jurisdiction of the courts of the Province of Ontario in any action or proceeding arising out of or relating to this Sixth Amendment.

  

	 	(c)	This Sixth Amendment may be signed in counterparts, each of which, when taken together, shall be deemed an original. Execution of this Sixth Amendment is effective if a
signature is delivered by facsimile transmission or electronic (e.g., pdf) transmission. 

[The remainder of this page is intentionally left blank] 

  
 - 3 -

 This Sixth Amendment has been agreed and accepted on the date first written above.

  

			
	ANGIOTECH PHARMACEUTICALS, INC.
		
	By:	 	   /s/ K. Thomas Bailey

		 	   Name:     K. Thomas Bailey
   Title:       Chief Financial Officer

	
	 AFMEDICA, INC.;
 AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.;
 ANGIOTECH AMERICA, INC.;

ANGIOTECH BIOCOATINGS CORP.;
 ANGIOTECH
DELAWARE, INC.;
 ANGIOTECH FLORIDA HOLDINGS, INC.;
 ANGIOTECH PHARMACEUTICALS (US), INC.;
 B.G. SULZLE, INC.;

MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.;
 NEUCOLL, INC.;
 QUILL MEDICAL, INC.;

SURGICAL SPECIALTIES CORPORATION; SURGICAL SPECIALTIES PUERTO RICO, INC.; and
 SURGICAL SPECIALTIES UK HOLDINGS LIMITED

		
	By:	 	   /s/ K. Thomas Bailey

		 	   Name:     K. Thomas Bailey
   Title:       President

			
	 ANGIOTECH INTERNATIONAL HOLDINGS CORP.; and

 
 0741693 B.C. LTD.

		
	By:	 	   /s/ Jay Dent

		 	   Name: Jay Dent

  Title: PresidentSeventh Agreement to Amend the Floating Rate Note Support Agreement

 Exhibit 10.2 
 Execution Version 
 SEVENTH AGREEMENT TO AMEND THE FLOATING RATE NOTE
SUPPORT AGREEMENT 
 THIS SEVENTH AMENDMENT is made as of this 22nd day of April, 2011. 

WHEREAS, (a) Angiotech Pharmaceuticals, Inc. (“Angiotech”), (b) the entities listed in Schedule
A (together with Angiotech, the “Companies” and each a “Company”), and (c) each of the other Consenting Noteholders party hereto, each Consenting Noteholder being a holder of and/or investment advisor or
manager with investment discretion over Floating Rate Notes, executed a Floating Rate Note Support Agreement dated as of October 29, 2010 concerning the principal aspects of an Exchange of Floating Rate Notes (as amended by an Agreement to
Amend the Floating Rate Note Support Agreement dated November 29, 2010, a Second Agreement to Amend the Floating Rate Note Support Agreement dated December 15, 2010, a Third Agreement to Amend the Floating Rate Note Support Agreement dated
January 11, 2011, a Fourth Agreement to Amend the Floating Rate Note Support Agreement dated January 27, 2011, a Fifth Agreement to Amend the Floating Rate Note Support Agreement dated February 7, 2011 and a Sixth Agreement to Amend
the Floating Rate Note Support Agreement dated February 22, 2011, the “Support Agreement”); 
 AND
WHEREAS, the Consenting Noteholders party to this seventh amendment (the “Seventh Amendment”) wish to further amend the Support Agreement in the manner set out in this Seventh Amendment; 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Companies
and the Consenting Noteholders party hereto hereby agree as follows: 
  

	1.	Capitalized Terms 

Capitalized terms that are used but not otherwise defined herein shall have the meanings ascribed thereto in the Support Agreement.

  

	2.	Consenting Noteholders Party to this Seventh Amendment 

 Each Consenting Noteholder party to this Seventh Amendment hereby represents and warrants, severally and not jointly, to each of the other parties to this Seventh Amendment (and acknowledges that each of
the other parties to this Seventh Amendment is relying upon such representations and warranties) that as of the date hereof: (a) it either (i) is the sole legal and beneficial owner of the principal amount of Floating Rate Notes disclosed
to Goodmans LLP as of such date, or (ii) has the investment and voting discretion with respect to the principal amount of Floating Rate Notes disclosed to Goodmans LLP as of such date; (b) it has the power and authority to bind the
beneficial owner(s) of such Floating Rate Notes to the terms of this Seventh Amendment; and (c) it has authorized and instructed Goodmans LLP to advise Angiotech, in writing, of the aggregate amount of Floating Rate Notes held by the Consenting
Noteholders that are party to this Seventh Amendment. 

	3.	Amendments to the Support Agreement 

 The Support Agreement is hereby amended as follows: 
  

	 	(a)	the definition of “Outside Date” on Schedule B to the Support Agreement is hereby deleted and replaced with the following: 

“Outside Date” means May 12, 2011. 
  

	4.	Support Agreement to apply in full force and effect 

 Except as expressly modified by the terms of this Seventh Amendment, the terms and conditions of the Support Agreement shall continue to apply in full force and effect, unamended. 

 

	5.	Miscellaneous 

  

	 	(a)	This Seventh Amendment shall be governed by and construed in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein,
without regard to principles of conflicts of law. Each of the parties to this Seventh Amendment submits to the jurisdiction of the courts of the Province of Ontario in any action or proceeding arising out of or relating to this Seventh Amendment.

  

	 	(b)	This Seventh Amendment may be signed in counterparts, each of which, when taken together, shall be deemed an original. Execution of this Seventh Amendment is effective
if a signature is delivered by facsimile transmission or electronic (e.g., pdf) transmission. 

[The remainder of this page is intentionally left blank] 

  
 - 2 -

 This Seventh Amendment has been agreed and accepted on the date first written above.

  

			
	ANGIOTECH PHARMACEUTICALS, INC.
		
	By:	 	   /s/ K. Thomas Bailey

		 	   Name:     K. Thomas Bailey
   Title:       Chief Financial Officer

  

			
	 AFMEDICA, INC.;
 AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.;
 ANGIOTECH AMERICA, INC.;

ANGIOTECH BIOCOATINGS CORP.;
 ANGIOTECH
DELAWARE, INC.;
 ANGIOTECH FLORIDA HOLDINGS, INC.;
 ANGIOTECH PHARMACEUTICALS (US), INC.;
 B.G. SULZLE, INC.;

MANAN MEDICAL PRODUCTS, INC.;
 MEDICAL
DEVICE TECHNOLOGIES, INC.; NEUCOLL, INC.;
 QUILL MEDICAL, INC.;
 SURGICAL SPECIALTIES CORPORATION;
 SURGICAL SPECIALTIES PUERTO RICO, INC.;
and
 SURGICAL SPECIALTIES UK HOLDINGS LIMITED

		
	By:	 	   /s/ K. Thomas Bailey

		 	   Name:     K. Thomas Bailey
   Title:       President

			
	 ANGIOTECH INTERNATIONAL HOLDINGS CORP.; and

 
 0741693 B.C. LTD.

		
	By:	 	   /s/ Jay Dent

		 	   Name:     Jay Dent
   Title:       President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}]]